Tolbutamide
- Generic Name
- Tolbutamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H18N2O3S
- CAS Number
- 64-77-7
- Unique Ingredient Identifier
- 982XCM1FOI
- Background
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both ba...
- Indication
For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05097716
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03723395
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Drug Interaction Study of CT1812 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Cognition Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT03716427
- Locations
- 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT03457597
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT03291288
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 36
- Registration Number
- NCT03103568
- Locations
- 🇩🇪
PAREXEL EPCU Berlin, Berlin, Germany
A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 18
- Registration Number
- NCT02473627
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
- Conditions
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02211079
Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02182401
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT01525628
- Locations
- 🇺🇸
1241.27.0006 Boehringer Ingelheim Investigational Site, La Mesa, California, United States
🇺🇸1241.27.0003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸1241.27.0004 Boehringer Ingelheim Investigational Site, Marlton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.